Defense World
14 Mar 2026, 05:13 UTC · 27w ago
Verdict
Headline takes no side. We score RLAY +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Guggenheim raised its price target for Relay Therapeutics (RLAY) from $15.00 to $22.00.
More positive than 93% of claims this week
Guggenheim maintains a 'Buy' rating on Relay Therapeutics.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 64% of claims this week
Relay Therapeutics shares reached a new 52-week high during mid-day trading on Friday.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The stock hit a 52-week high following a price target increase and a buy rating from Guggenheim.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
CNBC
4h ago
+74.0%
Price agrees with the score
$18.03 vs $10.36 close before publication (Mar 13) · not market-adjusted
RLAY chart →
